| 16.075 0.255 (1.61%) | 06-15 11:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.5 | 1-year : | 22.78 |
| Resists | First : | 16.7 | Second : | 19.5 |
| Pivot price | 15.65 |
|||
| Supports | First : | 15.62 |
Second : | 14.96 |
| MAs | MA(5) : | 15.83 |
MA(20) : | 15.62 |
| MA(100) : | 15.13 |
MA(250) : | 13.56 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.8 |
D(3) : | 49.2 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 16.87 | Low : | 7.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AUPH ] has closed below upper band by 15.6%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.16 - 16.24 | 16.24 - 16.3 |
| Low: | 15.57 - 15.68 | 15.68 - 15.77 |
| Close: | 15.67 - 15.83 | 15.83 - 15.96 |
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Mon, 08 Jun 2026
Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options - Stock Titan
Mon, 08 Jun 2026
Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant - Stock Titan
Sun, 07 Jun 2026
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million - The Motley Fool
Thu, 04 Jun 2026
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH) - Seeking Alpha
Thu, 07 May 2026
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 129 (M) |
| Shares Float | 126 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 60.2 (%) |
| Shares Short | 8,820 (K) |
| Shares Short P.Month | 8,890 (K) |
| EPS | 2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.34 |
| Profit Margin | 99.9 % |
| Operating Margin | 53.3 % |
| Return on Assets (ttm) | 13.6 % |
| Return on Equity (ttm) | 64.9 % |
| Qtrly Rev. Growth | 24.3 % |
| Gross Profit (p.s.) | 1.81 |
| Sales Per Share | 2.31 |
| EBITDA (p.s.) | 1.19 |
| Qtrly Earnings Growth | 56.2 % |
| Operating Cash Flow | 167 (M) |
| Levered Free Cash Flow | 125 (M) |
| PE Ratio | 7.44 |
| PEG Ratio | 0 |
| Price to Book value | 3.7 |
| Price to Sales | 6.93 |
| Price to Cash Flow | 12.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|